Sun Pharmaceutical Industries has announced that shareholders of US-based Organon & Co have approved the proposals related to the previously announced merger, marking a key milestone in the company's proposed acquisition of the pharmaceutical firm.

Under the transaction, Organon will become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA, an indirect wholly owned subsidiary of Sun Pharma. The shareholder approval advances the acquisition process, although the transaction remains subject to regulatory clearances and other customary closing conditions.

Sun Pharma had announced the acquisition in April 2026 in a deal valued at approximately $9.4 billion, including debt. The transaction is the largest acquisition in the company's history and is expected to be completed by early 2027, subject to all necessary approvals.

The acquisition is expected to strengthen Sun Pharma's global presence, particularly in women's health and established medicines. Organon, which was spun off from Merck & Co in 2021, operates a diversified portfolio comprising women's health products, biosimilars, and established pharmaceutical brands across international markets.

For Sun Pharma, the transaction is expected to diversify its revenue mix beyond specialty medicines and generic drugs while providing access to a portfolio of mature brands with stable cash flows. The company stated that the shareholder approval represents a significant step toward completing the acquisition and has not announced any change to its expected timeline for closing the deal.